linjc16/ctgov huggingface dataset:
Airtraq Versus Standard Direct Laryngoscopy in the Pediatric Airway

Study Overview
=================
Brief Summary
-----------------
Time to intubate, view to glottic opening and success rate are not different when Airtraq technique is used compared to standard direct laryngoscopy in children.

Detailed Description
-----------------
50 children (age 5 years and 11 month or younger) with expected easy intubation, scheduled for elective surgery requiring endotracheal intubation are enrolled.

Official Title
-----------------
A Comparison of the Airtraq and Standard Direct Laryngoscopy in the Pediatric Airway - A Randomized Trial.

Conditions
-----------------
Endotracheal Intubation

Intervention / Treatment
-----------------
* Device: Airtraq
* Device: Direct Laryngoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: elective surgery requiring endotracheal intubation Exclusion Criteria: predicted difficult bag-mask ventilation predicted difficult intubation rapid sequence induction emergency endotracheal intubation hemodynamic instability emergency surgery non-english speaking caregivers/parents

Ages Eligible for Study
-----------------
Maximum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Airtraq<br>Intubation with the use of the Airtraq | Device: Airtraq<br>* Intubation using Airtraq<br>|
| Active Comparator: Direct Laryngoscopy<br>Intubation using direct laryngoscopy | Device: Direct Laryngoscopy<br>* Intubation using direct laryngoscopy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to intubation |  | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of glottic opening seen |  | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
intubation, Airtraq, pediatric, airway
Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm

Study Overview
=================
Brief Summary
-----------------
Antidepressants are among the most widely prescribed medications, yet only 35-45% of patients achieve remission following an initial antidepressant trial. The financial burden of treatment failures in direct treatment costs, disability, decreased productivity, and missed work may in part derive from a mismatch between optimal, and actual, medications prescribed. The present one year retrospective study seeks to evaluate the indirect and direct healthcare costs for 96 patients with a DSM-IV-TR depressive or anxiety disorder, in relation to an interpretive reporting system designed to predict antidepressant responses based on DNA variations in cytochrome P450 genes (CYP2D6, CYP2C19, CYP1A2), the serotonin transporter gene (SLC6A4), and the serotonin 2A receptor (5HTR2A) genes.

Official Title
-----------------
A Retrospective Analysis of Outcomes in Outpatients With Major Depressive Disorder (MDD) in a Staff Model HMO: Pharmacogenetic Algorithm for Psychotropic Pharmacotherapeutic Applications

Conditions
-----------------
Depression, Anxiety

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major Depressive Disorder Dysthymic Disorder Depressive Disorder NOS Obsessive Compulsive Disorder (OCD) Generalized Anxiety Disorder Panic Disorder Anxiety Disorder NOS Post-Traumatic Stress Disorder (PTSD) Social Phobia Exclusion Criteria: Bipolar Disorder Schizophrenia Schizoaffective Disorder Previous pharmacogenomic testing

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Depression and anxiety<br>Subjects with a primary diagnosis of depression or anxiety disorder. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Outpatient Visits | Number of outpatient healthcare visits during study window | During the one year study window (April 1, 2010 to April 1, 2011) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Medical Absence Days | Number of medical absence days during study window | During the one year study window (April 1, 2010 to April 1, 2011) | 
| Number of Disability Claims | Number of disabiity claims during study window | During the one year study window (April 1, 2010 to April 1, 2011) |
Evaluation, the Histomorphometric Study of Nanocrystalline Hydroxyapatite (Nano Bone) Wif Lovastatin in the Preservation of the Tooth Socket

Study Overview
=================
Brief Summary
-----------------
Twenty patients referring to periodontics department of Boroujerd Azad university of dentistry after obtaining consent to participate in the research project, which have more than 20 teeth, are over 18 years old and require socket preservation surgery to tooth extraction for the periodontal problem, caries or Fractures were selected.

Detailed Description
-----------------
twenty healthy patients referring to periodontics department of Boroujerd Azad university of dentistry after obtaining consent to participate in the research project, which has more than 20 teeth, are over 18 years old and require socket preservation surgery to tooth extraction for the periodontal problem, caries or Fractures were selected. moreover, divided the socket randomly to two groups(A, B)including A: bone graft with lovastatin and B: bone graft alone, after 3 months with trephine will collect the samples. following the histomorphometric analysis.

Official Title
-----------------
the Histomorphometric Study of Nanocrystalline Hydroxyapatite (Nano Bone) With Lovastatin in the Preservation of the Tooth Socket

Conditions
-----------------
Bone Loss

Intervention / Treatment
-----------------
* Drug: Lovastatin 40 MG
* Procedure: without drug with Bone graft


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: at least 18 years old tooth fracture, root caries Patients are volunteered for placement of the implant Exclusion Criteria: systemic diseases Pregnancy and breastfeeding malignancy, radiation therapy, history of periodontal surgery during the six months ago. medicine(phosphonates, antibiotic,...)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: lovastatin 40 mg with bone graft<br>after tooth extraction, put teh lovastatin40 mg wif bone graft wifin tooth socket | Drug: Lovastatin 40 MG<br>* after tooth extraction, put teh lovastatin40 mg wif bone graft wifin tooth socket<br>* Other names: Group A;|
| Active Comparator: without drug with bone graft<br>after tooth extraction, put the bone graft wifin tooth socket | Procedure: without drug with Bone graft<br>* after tooth extraction, put teh bone graft wifin tooth socket<br>* Other names: Group B;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Socket preservation with Lovastatin as evaluated by the amount of bone formation volume |  | 3 month |
GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

Study Overview
=================
Brief Summary
-----------------
An observational study to evaluate the natural progression of dry AMD in genetically defined subjects

Detailed Description
-----------------
Prospective, observational study to evaluate the natural progression of anatomical and functional visual parameters in genetically defined subjects with GA due to AMD.

Official Title
-----------------
A Study of Disease Progression in Genetically Defined Subjects With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Conditions
-----------------
Dry Age-related Macular Degeneration, Macular Degeneration, Retinal Disease, Retinal Degeneration, Geographic Atrophy, Macular Atrophy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults with unilateral or bilateral Geographic Atrophy (GA) due to Age-related Macular Degeneration (AMD) BCVA of 40 letters or better using ETDRS charts Exclusion Criteria: Evidence or history of neovascular Age-related Macular Degeneration (AMD) or diabetic retinopathy Significant ocular or non-ocular disease that would impact the subject's ability to participate in the study Participation in another research study involving an investigational product within the previous 4 weeks or 5 half-lives whichever is longer from the screening/baseline OR received a gene/cell therapy at any time previously

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Geographic Atrophy (GA) | Change from baseline in area of Geographic Atrophy, as assessed by Fundus Auto Fluoresence measured in mm2 | Up to 96 weeks | 
| Colour Fundus (CF) | Change from baseline in Colour Fundus Photography measured in mm2 | Up to 96 weeks | 
| Retinal Drusen Volume | Change from baseline in retinal drusen volume measured in mm3 | Up to 96 weeks | 
| Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) | Change from baseline in ETDRS BCVA reading score | Up to 96 weeks | 
| Retinal sensitivity | Change from baseline in retinal sensitivity as assessed by microperimetry | Up to 96 weeks | 
| Visual Functioning Questionnaire | Change from baseline in National Eye Institute Visual Functioning Questionnaire 25-Items Version (NEI VFQ-25) Minimum Score (Best) = 29. Maximum score (Worst) = 149 | Up to 96 weeks | 
| Medical Events of Interest (MEI) | Change from baseline in percentage of Participants with MEI | Up to 96 weeks | 
| Monocular and Binocular Reading Performance | Change in Monocular and Binocular Reading Performance measured in words/min | Up to 96 weeks |
Radiofrequency Ablation Using Octopus Electrodes for Small Hepatocellular Carcinoma With No-touch Technique

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate clinical outcome of RFA for small single nodular HCC using no touch technique with separable clustered electrode (Octopus) in a prospective multicenter manner Participating center: Seoul national university hospital, Asan medical center, Samsung medical center, Kunkuk university hospital, St. mary's Seoul hospital

Official Title
-----------------
Radiofrequency Ablation Using Octopus Electrodes for Small Hepatocellular Carcinoma With No-touch Technique: A Prospective Single Arm Study

Conditions
-----------------
Hepatocellular Carcinoma, Radiofrequency Ablation

Intervention / Treatment
-----------------
* Procedure: RFA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Child-Pugh class A liver function 1 - 2.5 cm sized Single nodular HCC without history of previous HCC treatment or with evidence of no recurrence at least 2 years after previous HCC treatment Exclusion Criteria: more than 2 HCC tumor size larger than 2.5 cm Child-Pugh class B or C liver function invisible tumor even after real-time fusion US guidance accompanied by vascular invasion or distant metastasis presence of coagulopathy defined as platelet count < 50,000/mm3 and/or PT-INR > 50%

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: No touch group<br>RFA for small HCC would be done by using no touch technique | Procedure: RFA<br>* thermal ablation using radiofrequency for HCC<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 1 year local tumor progression | cumulative incidence of local tumor progression after RFA | 1 year after procedure |
The Massachusetts General Hospital Optical Coherence Tomography Registry

Study Overview
=================
Brief Summary
-----------------
Information will be collected prospectively in about 3,000 patients having Optical Coherence Tomography during cardiac catheterization. Subjects will be initially enrolled at sites outside of the United States, where Optical Coherence Tomography is approved by regulatory agencies. Subjects will be followed for up to 5 years.

Detailed Description
-----------------
This project will create a prospective registry of 3,000 patients with follow-ups of up to 5 years. The aims of the project will be: identify plaque characteristics on OCT that are associated with adverse cardiac events including myocardial infarction to identify characteristics of stented arteries that are associated with adverse events including restenosis and stent thrombosis Because detailed clinical, angiographic and intravascular imaging data will be gathered from a large number of patients with clinical follow-ups, we anticipate that the registry will be a tremendous resource for additional research questions going forward.

Official Title
-----------------
The Massachusetts General Hospital Optical Coherence Tomography Registry

Conditions
-----------------
Coronary Artery Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects who have had OCT imaging performed during cardiac catheterization and have provided written consent Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major adverse cardiac events (MACE) |  | 1 year |
Variations of the Lung Compliance During Extracorporeal Circulation and Post Operative Pulmonary Complications

Study Overview
=================
Brief Summary
-----------------
the decrease in thoracopulmonary compliance after cardiac surgery is well known . The investigators hypothesize that the major factor determining pulmonary outcome after cardiac surgery is the alteration of pulmonary compliance during cardiopulmonary bypass(CBP) and that this alteration is due to CBP itself through pulmonary blood emptying.

Detailed Description
-----------------
compliance is the compliance calculate when thorax is closed, the pulmonary compliance is the compliance calculated when thorax is opened After operation chest X-ray are daily done and blood samples as needed. Were recorded death, time of extubation,duration of non invasive ventilation,of Intensive Care Unit stay and of total hospital stay, troponin peak, lactates, blood gases, ionogram and count.Variations of compliance is analyzed through one factor paired Anova or Wilcoxon paired test. Decrease of compliance and respiratory complications are analyzed through binomial logistic regression.

Official Title
-----------------
Variations of the Lung Compliance During Extracorporeal Circulation and Post Operative Pulmonary Complications

Conditions
-----------------
Thoracic Surgery, Cardiopulmonary Bypass

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: scheduled for standard aortic mitral or coronary surgery Exclusion Criteria: emergency operation no complete preoperative echocardiography surgery needing multiple table position changes unstable cardiac or respiratory condition difficult patient needing multiple care and/or special attention

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pulmonary compliance during cardiac surgery | compliance is calculated by dividing tidal volume (ml) by the difference between plateau-inspiratory pressure (mmHg) and end-expiratory pressure (mmHg) before ,during and after CBP | intraoperative | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pulmonary complications including death after cardiac surgery | intersticial and/or alveolar pulmonary oedema leading to death or extra hospital stay | 1 month | 
| thoracopulmonary compliance during cardiac surgery | compliance is calculated by dividing tidal volume (ml) by the difference between peak-inspiratory pressure (mmHg) and end-expiratory pressure (mmHg) before ,during and after CBP | intraoperative | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cardiac surgery, thoracopulmonary compliance
Cholesterol Metabolism in Heterozygous Phytosterolemia

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to examine the effect of plant sterols on cholesterol absorption and synthesis in people with heterozygous phytosterolemia.

Detailed Description
-----------------
A plant sterol supplementation study will be conducted in individuals who are heterozygous for phytosterolemia compared to non-carriers. The study will use a double-blind, randomised, crossover, placebo-controlled design in which participants will consume 2 treatments including 1.6 g of plant sterol pills and a placebo pill, each for 4 weeks. A 4 week washout period will separate the two treatment periods. Plant sterol concentrations will be measured by gas liquid chromatography and absorption will be measured by the ratio of campesterol to lathosterol in plasma. Cholesterol absorption and synthesis will be measured by dual stable isotope technique, involving simultaneous administration of 13C-cholesterol and deuterium oxide, respectively.

Official Title
-----------------
Assessment of Cholesterol Metabolism in Heterozygous Phytosterolemia

Conditions
-----------------
Cardiovascular Disease

Intervention / Treatment
-----------------
* Dietary Supplement: phytosterol ester


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: heterozygous for phytosterolemia, wild-type. Exclusion Criteria: Pregnant, Previous heart attack, Kidney disease.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Phytosterol ester<br>Plant sterol compared with placebo | Dietary Supplement: phytosterol ester<br>* 1.6 g phytosterols/day for 29 days<br>* Other names: Phytocell Phytosterols, NPN#: 80012048;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Decrease in plasma LDL-cholesterol | Other studies have found 10% reduction in plasma LDL-cholesterol after 2.2-3.2 gram of plant sterol supplementation for 4 weeks in heterozygous phytosterolemia. | 29 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Increase plasma plant sterols | We will use a control group and compare the level of increase in plasma plant sterol levels in both group over the course of plant sterol consumption | 29 days |
Impact of Containment and the Current Epidemic on the Sexual Risk-taking of People Using PrEP to Prevent HIV Infection.

Study Overview
=================
Brief Summary
-----------------
People using PrEP to prevent HIV infection have sexual risk-taking behaviors that motivated the prescription of PrEP. Both containment and the current epidemic may affect the sexual behavior of people using PrEP and the risk of acquiring STIs. Hypotheses regarding the impact of the current epidemic-motivated confinement and its gradual lifting are as follows: A decrease in sexual risk-taking during the confinement period, followed by an increase when the confinement is lifted. An increase in sexual violence and the use of psychoactive substances. An impact on PrEP monitoring and compliance. An increase in the incidence of STIs when the confinement is lifted.

Official Title
-----------------
Impact of Containment and the Current Epidemic on the Sexual Risk-taking of People Using PrEP to Prevent HIV Infection.

Conditions
-----------------
PREP

Intervention / Treatment
-----------------
* Other: Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: People using PrEP for HIV prevention being followed up at Tourcoing hospital Having given their consent to participate in this study Beneficiary of a social insurance plan or entitled person Exclusion Criteria: Minor patient Refusal to participate Trusteeship Curatorship

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PrEP patients undergoing follow-up at Tourcoing hospital<br> | Other: Questionnaire<br>* Questionnaire<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Impact of the current epidemic on sexual risk taking of Prep users in the number of partners per month |  | At day 1 | 
| Impact of the current epidemic on sexual risk taking of Prep users in the number of sexual encounters per month |  | At day 1 | 
| Impact of the current epidemic on sexual risk taking of Prep users in the frequency of condom use during anal intercourse |  | At day 1 |